Men, there’s groundbreaking news in the fight against prostate cancer: a new urine test called MyProstateScore 2.0 (MPS2) is demonstrating remarkable accuracy in detecting clinically significant cancers, potentially sparing countless men from unnecessary biopsies, a common worry among men.
Published in JAMA Oncology, the study led by Dr. Jeffrey Tosoian of Vanderbilt University Medical Center reveals that MPS2 outperforms traditional biomarker tests, including the PSA test, by analyzing 18 genes associated with prostate cancer. Study results showed that of the nearly 800 patients recruited for this research with an elevated PSA level, the new test excelled in accurately confirming the absence of clinically significant prostate cancer.
MPS2 test offers precision diagnosis, reducing unnecessary biopsies
Prostate cancer ranks as the second most widespread and fatal cancer among men in the United States. However, while widely used, the PSA test often leads to false positives, prompting numerous invasive biopsies. These biopsies, while generally safe, carry risks and discomfort.
Enter MPS2. This test acts as a precision tool, honing in on aggressive, clinically significant cancers while minimizing unnecessary interventions for harmless ones. The study suggests that MPS2 could have prevented up to 42% of unnecessary biopsies without missing any critical cancers.
While other second-line tests like MRI scans exist, they are only sometimes available and can yield subjective results. In contrast, MPS2 offers a standardized, reliable approach without requiring specialized equipment.
Perhaps most importantly, if MPS2 clears you, there may be no need for further invasive procedures like MRI scans or biopsies. It’s a potential game-changer in prostate cancer diagnosis, offering a path to reduce unnecessary burdens on patients.
Ongoing research is investigating the effectiveness of MPS2 in other ethnicities that may be at higher risk for prostate cancer, since the study primarily involved participants of non-African American ethnicity.
If you’re facing concerns about prostate cancer, discussing MPS2 with your healthcare provider could lead to a more informed and potentially less invasive path forward.
Dr. David Samadi is the Director of Men’s Health and Urologic Oncology at St. Francis Hospital in Long Island. He’s a renowned and highly successful board certified Urologic Oncologist Expert and Robotic Surgeon in New York City, regarded as one of the leading prostate surgeons in the U.S., with a vast expertise in prostate cancer treatment and Robotic-Assisted Laparoscopic Prostatectomy. Dr. Samadi is a medical contributor to NewsMax TV and is also the author of The Ultimate MANual, Dr. Samadi’s Guide to Men’s Health and Wellness, available online both on Amazon and Barnes & Noble. Visit Dr. Samadi’s websites at robotic oncology and prostate cancer 911.
